Skip to content. | Skip to navigation

Garvan Institute

Sections
 

About Us

 

Dr Colin ("Charlie") K.W. Watts

 

Project Leader, Cancer Therapeutics Development Laboratory, Cancer Research Program, Garvan Institute of Medical Research

Email: c.watts 'at' garvan.org.au
Research Group: Cancer Therapeutics Development Laboratory

 
 
Dr Watts joined the Garvan in 1990, after post-doctoral studies at the ICRF in London. His research has been concerned with steroid and steroid antagonist action in breast cancer, in particular the mechanisms by which these control cell proliferation and the identification and characterisation of novel cancer-related genes. Recent research has focused on one of these, the ubiquitin ligase EDD, which is critical during embryonic development and is involved in several pathways including DNA repair mechanisms.
 
 
 

After working independently for several years, Dr Watts returned to the Garvan in 2010 and now leads a project to develop novel drugs targeting the altered metabolic pathways of cancers.

Education

PhD, University of Sydney, Australia
B. Sc. Hons (First Class), University of Otago, New Zealand

Selected Publications

O’Brien PM, Davies MJ, Scurry J, Smith AN, Barton CA, Henderson MJ, Saunders DN, Gloss BS, Patterson KI, Clancy JL, Heinzelmann-Schwarz VA, Murali R, Scolver RA, Zeng Y, Williams ED, Scurr L, DeFazio A, Quinn DI, Watts CKW, Hacker NF, Henshall SM, Sutherland RL. (2008). The E3 ubiquitin ligase EDD is an adverse prognostic factor for serous epithelial ovarian cancer. and modulates cisplatin resistance in vitro. Br. J. Cancer 998: 1085-1093

Ohshima R, Ohta T, Wu W, Koike A, Iwatani T, Henderson M, Watts CKW, and Otsubo T (2007). Putative tumor suppressor EDD interacts with and up-regulates APC. Genes to Cells 12:1339-4135

Munoz M, Saunders DN, Henderson MJ, Clancy JL, Russell AJ, Lehrbach G, Musgrove EA, Watts CKW and Sutherland RL (2007). The E3 ubiquitin ligase EDD regulates S Phase and G2/M DNA Damage Checkpoints. Cell Cycle. 6:3070-3077

Butt AJ, Roberts CG, Seawright AA, Oelrichs PB, Macleod JK, Liaw TY, Kavallaris M, Somers-Edgar TJ, Lehrbach GM, Watts CKW, Sutherland RL. (2006). A novel plant toxin, persin, with in vivo activity in the mammary gland, induces Bim-dependent apoptosis in human breast cancer cells. Mol Cancer Ther. 5:2300-2309

Henderson MJ, Munoz MA, Saunders DN, Clancy JL, Russell AJ, Williams B, Pappin D, Khanna KK, Jackson SP, Sutherland RL, Watts CKW (2006). EDD mediates DNA damage-induced activation of CHK2. J. Bio.l Chem. 281:39990-40000

Saunders DN, Hird SL, Withington SL, Dunwoodie SL, Henderson MJ, Biben C, Sutherland RL, Ormandy CJ, Watts CKW (2004). Edd, the murine hyperplastic discs gene, is essential for yolk sac vascularization and chorioallantoic fusion. Mol. Cell. Biol. 24(16):7225-34

Clancy, JL, Henderson, MJ, Russell AJ, Anderson, DW, Bova, RJ, Campbell, IG, Choong, DYH, Macdonald, GA, Mann, GJ, Nolan, T, Brady, G, Olopade, OI, Woollatt, E, Davies, MJ, Segara, D, Hacker, NF, Henshall, SM, Sutherland, RL, Watts, CKW (2003). EDD, the human orthologue of the hyperplastic discs tumour suppressor gene, is amplified and overexpressed in cancer. Oncogene. 22:5070-5081

Eblen S, Kumar NV, Shah K, Henderson MJ, Watts CKW, Shokat KM, and Weber MJ. (2003) Identification of novel ERK2 substrates through use of an engineered kinase and ATP analogs. J. Biol. Chem. 278:14926-14935

Leung K-C, Ballesteros M, Doyle N, Watts CKW, Low T-H, Ross RJM and Ho KY (2003) Estrogen inhibits growth homone (GH) signalling by suppressing GH-induced JAK2 phosphorylation. Proc. Natl. Acad. Sci. USA. 100:1016-1021

Henderson MJ, Russell AJ, Hird S, Munoz M, Clancy JL, Lehrbach GM, Calanni ST, Jans DA, Sutherland RL and Watts CKW (2002) EDD, the human hyperplastic discs protein, has a role in progesterone receptor coactivation and potential involvement in DNA damage response. J Biol Chem. 277:26468-26478

 

 

Search for all publications by CK Watts

 

 

 
 
 
Personal tools